Search

Aim: The aim of the article was to examine the relationship between healthcare workers' (HCW) antibody responses to the inactivated SARS-CoV-2 vaccine and the division in which they are employed. Material and methods: Study data were obtained retrospectively from hospital medical records. 90.8% of participants (n = 177) who had received 2 doses of the inactivated SARS-CoV-2 vaccine but who had not had COVID-19 disease before and whose polymerase chain reaction (PCR) test positivity was not detected, without acquired or primary immunodeficiency and not using immunosuppressive drugs, and tested for SARS-CoV-2 antibodies between 7 and 14 days after the second dose of the vaccine, were included in our study. The control group consisted of 9.2% (n = 18) unvaccinated individuals with the same characteristics. Results: The study included 177 people who received 2 doses of the inactivated SARS-CoV-2 vaccine and 18 people who had never been vaccinated, for a total of 195 HCWs. When the SARS-CoV-2 antibody test results of the participants were examined, it was found that 6.2% (n = 12) of the antibody level was negative, 24.1% (n = 47) was positive with a low antibody response between 1 and 10, and 69.7% (n = 136) was positive with a high antibody response. There was no statistically significant difference (p > 0.05) observed in the antibody level results of HCWs who received the SARS-CoV-2 vaccination. Among HCWs who had received vaccinations, the rate of SARS-CoV-2 IgG negativity was 2/177 (1%) and the rate of seroconversion was 175/177 (99%). Conclusions: The SARS-CoV-2 IgG negativity rate was 1% and the seroconversion rate was 99% in vaccinated HCWs. There was no statistically significant difference in the SARS-CoV-2 antibody results according to the occupations of the HCWs. [ABSTRACT FROM AUTHOR]

Copyright of Sakarya Tıp Dergisi is the property of Sakarya Tip Dergisi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Cutaneous mastocytosis defines a group of diseases categorized by the existence of augmented numbers of mast cells in the dermis. Cases with cutaneous mastocytosis do not meet diagnostic conditions for systemic mastocytosis and demonstrate no proof of organ participation other than the dermis. This article after mentioning history, prevalence, and classification briefly reviews clinical features and triggers of mast cell activation and lastly discusses the management of cutaneous mastocytosis under the light of current observations in detail. Patients with cutaneous mastocytosis often be influenced by mast cell mediator-linked symptoms, which are often commenced by pressures on the dermal lesions. Management of cutaneous mastocytosis is chiefly built on avoiding triggers of mast cells. The availability of epinephrine autoinjectors in case of severe systemic reactions such as anaphylaxis and utilizing antihistamines when symptoms occur to establish the backbone of treatment in cutaneous mastocytosis cases. [ABSTRACT FROM AUTHOR]

Introduction: Measles, mumps, and rubella (MMR) vaccine is a part of the childhood routine immunization program. It is known that allergic reactions, from urticaria to anaphylaxis, may develop against MMR vaccines containing trace amounts of egg protein and other ingredients. Aim: To determine whether children with any degree of egg allergy show allergic reactions to the MMR vaccine application and to draw attention to the fact that children without a history of anaphylaxis can be vaccinated safely by practitioners and/or family physicians in health centers. Material and methods: The files of 90 patients who were vaccinated between 2017 and 2022 in the pediatric allergy clinic were retrospectively analyzed. These patients were those who were followed up due to egg allergy in our outpatient clinic or were referred from the family health centers because the family said that the baby had an egg allergy. Results: A total of 94 doses of vaccination were given to 90 patients. Four doses were for those who were vaccinated for a second time. All skin prick tests with 94 doses of MMR vaccine were negative, and only 1 patient (1/94, 1.06%) developed nonspecific macular rash 0.5 h after vaccination. No other allergic reactions or anaphylaxis were observed. Conclusions: No serious allergic reaction developed after MMR vaccination in IgE-mediated egg allergy patients. We think that there is no harm in administering MMR vaccine to these patients in family health centers where other vaccines are applied, without testing with the vaccine and without the need for divided doses. [ABSTRACT FROM AUTHOR]